Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008
- PMID: 21440669
- DOI: 10.1016/j.cgh.2011.03.020
Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008
Abstract
Background & aims: Chronic liver diseases (CLDs) are major causes of morbidity and mortality worldwide. We assessed changes in the prevalence of different types of CLD in the United States.
Methods: National Health and Nutrition Examination Surveys conducted between 1988 and 2008 were used to estimate changes in the prevalence and predictors of CLDs. Serologic and clinical data were used to establish the diagnoses of CLDs in 39,500 adults. Statistical analyses were conducted with SUDAAN 10.0 (SAS Institute, Inc, Cary, NC).
Results: The prevalence rates for CLD were 11.78% (1988-1994), 15.66% (1999-2004), and 14.78% (2005-2008). During the same period, the prevalence of hepatitis B virus infection (0.36%, 0.33%, and 0.34%), hepatitis C virus (1.95%, 1.97%, and 1.68%), and alcoholic liver disease (1.38%, 2.21%, and 2.05%) remained generally stable. In contrast, the prevalence of nonalcoholic fatty liver disease (NAFLD) increased from 5.51% to 9.84% to 11.01%. From 1988 to 1994, NAFLD accounted for 46.8% of CLD cases; from 1994 to 2004 its prevalence increased to 62.84%, and then to 75.1% from 2005 to 2008. During these time periods, steady increases were observed in obesity (21.74%, 30.02%, and 33.22%), visceral obesity (35.18%, 48.16%, and 51.43%), type II diabetes (5.55%, 7.88%, and 9.11%), insulin resistance (23.29%, 32.50%, and 35.00%), and hypertension (22.68%, 33.11%, and 34.08%). A multivariate analysis showed that during all time periods, obesity was an independent predictor of NAFLD.
Conclusions: National Health and Nutrition Examination Surveys data collected from 1988 to 2008 show that the prevalence of major causes of CLD remained stable, except for NAFLD, which increased steadily, along with the prevalence of metabolic conditions. Given the increasing rates of obesity, NAFLD prevalence is expected to contribute substantially to the burden of CLD in the United States.
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Etiologies of chronic liver diseases in Hong Kong.Eur J Gastroenterol Hepatol. 2007 Aug;19(8):659-64. doi: 10.1097/MEG.0b013e3281ace0b7. Eur J Gastroenterol Hepatol. 2007. PMID: 17625435
-
The epidemiology of newly diagnosed chronic liver disease in gastroenterology practices in the United States: results from population-based surveillance.Am J Gastroenterol. 2008 Nov;103(11):2727-36; quiz 2737. doi: 10.1111/j.1572-0241.2008.02071.x. Epub 2008 Jul 31. Am J Gastroenterol. 2008. PMID: 18684170
-
Long-term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 patients.Bone Marrow Transplant. 2000 Sep;26(6):649-55. doi: 10.1038/sj.bmt.1702532. Bone Marrow Transplant. 2000. PMID: 11035372
-
Liver disease in older women.Maturitas. 2010 Mar;65(3):210-4. doi: 10.1016/j.maturitas.2009.11.010. Epub 2009 Dec 3. Maturitas. 2010. PMID: 19962256 Review.
-
Impact of diabetes on the severity of liver disease.Am J Med. 2007 Oct;120(10):829-34. doi: 10.1016/j.amjmed.2007.03.025. Am J Med. 2007. PMID: 17904449 Review.
Cited by
-
Discordance Between Child-Pugh and National Cancer Institute Classifications for Hepatic Dysfunction: Implications on Dosing Recommendations for Oncology Compounds.J Clin Pharmacol. 2021 Jan;61(1):105-115. doi: 10.1002/jcph.1702. Epub 2020 Jul 20. J Clin Pharmacol. 2021. PMID: 32691438 Free PMC article.
-
Imaging Biomarkers of Hepatic Fibrosis: Reliability and Accuracy of Hepatic Periportal Space Widening and Other Morphologic Features on MRI.AJR Am J Roentgenol. 2021 May;216(5):1229-1239. doi: 10.2214/AJR.20.23099. Epub 2021 Mar 17. AJR Am J Roentgenol. 2021. PMID: 33729883 Free PMC article.
-
Risk factor compositions of nonalcoholic fatty liver disease change with body mass index in males and females.Oncotarget. 2016 Jun 14;7(24):35632-35642. doi: 10.18632/oncotarget.9691. Oncotarget. 2016. PMID: 27248665 Free PMC article.
-
Effect of dietary advanced glycation end products on mouse liver.PLoS One. 2012;7(4):e35143. doi: 10.1371/journal.pone.0035143. Epub 2012 Apr 4. PLoS One. 2012. PMID: 22496902 Free PMC article.
-
Chronic NOS inhibition accelerates NAFLD progression in an obese rat model.Am J Physiol Gastrointest Liver Physiol. 2015 Mar 15;308(6):G540-9. doi: 10.1152/ajpgi.00247.2014. Epub 2015 Jan 8. Am J Physiol Gastrointest Liver Physiol. 2015. PMID: 25573175 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical